Abstract
The processing of the Amyloid Precursor Protein (APP) is a critical event in the formation of amyloid plaques which are composed of the 4kDa amyloid β-peptide (Aβ). Processing of APP occurs through a non-amyloidogenic pathway, mediated by initial α-secretase cleavage or through an amyloidogenic pathway via sequential cleavage by β- and γ- secretase enzymes, which produces Aβ peptides. Currently, the diagnosis of probable or possible Alzheimers disease (AD) is primarily based on neuropsychological and neuroradiological assessment. Recent reports indicate that platelet β- secretase activity is moderately increased in patients with AD and mild cognitive impairment (MCI). To our knowledge platelet α-secretase activity has not yet been explored in this context and estimation of the ratio of the activities of α- and β-secretase in platelets may represent a useful surrogate marker of the balance between the two pathways of APP metabolism and be of importance for the diagnosis of AD. We therefore considered it of interest to develop assays of platelet α- and β-secretase activities suitable for such clinical investigations. Application of these assays to a Swedish population failed to uncover an effect of AD or MCI on individual platelet secretase activities or the secretase ratio. However, we did observe an inverse correlation between plasma triacylglycerol (TAG) levels and the secretase ratio. The results are discussed in the context of the clinical usefulness of the secretase ratio as a biochemical adjunct to the diagnosis of AD.
Keywords: α-secretase, β-secretase, Alzheimer's disease, biomarkers
Current Alzheimer Research
Title: Platelet Alpha- and Beta- Secretase Activities are not Significantly Affected by Dementia or Mild Cognitive Impairment in Swedish Patients
Volume: 7 Issue: 2
Author(s): P. Gorham, N. Bark, S. Meaney, I. Bjorkhem and M. Crisby
Affiliation:
Keywords: α-secretase, β-secretase, Alzheimer's disease, biomarkers
Abstract: The processing of the Amyloid Precursor Protein (APP) is a critical event in the formation of amyloid plaques which are composed of the 4kDa amyloid β-peptide (Aβ). Processing of APP occurs through a non-amyloidogenic pathway, mediated by initial α-secretase cleavage or through an amyloidogenic pathway via sequential cleavage by β- and γ- secretase enzymes, which produces Aβ peptides. Currently, the diagnosis of probable or possible Alzheimers disease (AD) is primarily based on neuropsychological and neuroradiological assessment. Recent reports indicate that platelet β- secretase activity is moderately increased in patients with AD and mild cognitive impairment (MCI). To our knowledge platelet α-secretase activity has not yet been explored in this context and estimation of the ratio of the activities of α- and β-secretase in platelets may represent a useful surrogate marker of the balance between the two pathways of APP metabolism and be of importance for the diagnosis of AD. We therefore considered it of interest to develop assays of platelet α- and β-secretase activities suitable for such clinical investigations. Application of these assays to a Swedish population failed to uncover an effect of AD or MCI on individual platelet secretase activities or the secretase ratio. However, we did observe an inverse correlation between plasma triacylglycerol (TAG) levels and the secretase ratio. The results are discussed in the context of the clinical usefulness of the secretase ratio as a biochemical adjunct to the diagnosis of AD.
Export Options
About this article
Cite this article as:
Gorham P., Bark N., Meaney S., Bjorkhem I. and Crisby M., Platelet Alpha- and Beta- Secretase Activities are not Significantly Affected by Dementia or Mild Cognitive Impairment in Swedish Patients, Current Alzheimer Research 2010; 7 (2) . https://dx.doi.org/10.2174/156720510790691254
DOI https://dx.doi.org/10.2174/156720510790691254 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitigating Alzheimer’s Disease with Natural Polyphenols: A Review
Current Alzheimer Research Studies on the Transdermal Delivery of Nimodipine from a Menthol-based TTS in Human Volunteers
Current Drug Delivery VIP in Neurological Diseases: More Than A Neuropeptide
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in the Treatment of Neurogenic Erectile Dysfunction
Recent Patents on CNS Drug Discovery (Discontinued) Drosophila Models of Proteinopathies: the Little Fly that Could
Current Pharmaceutical Design Haptoglobin Phenotype May Alter Endothelial Progenitor Cell Cluster Formation in Cerebral Small Vessel Disease
Current Neurovascular Research Pharmacological Approaches of Alzheimer's Disease: An Update
Current Drug Therapy Humanized Mouse Models of HIV-1 Latency
Current HIV Research Effects of Transition Metals in the Conversion Mechanism of Prion Protein and in the Pathogenesis of Prion Diseases
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Rashes, Sniffles, and Stroke: A Role for Infection in Ischemic Stroke of Childhood
Infectious Disorders - Drug Targets n-3 Fatty Acids: Role in Neurogenesis and Neuroplasticity
Current Medicinal Chemistry Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?
Current Pharmaceutical Design Covid-19 in Man: A Very Dangerous Affair
Endocrine, Metabolic & Immune Disorders - Drug Targets Smoking and Hypertension: Independent or Additive Effects to Determining Vascular Damage?
Current Vascular Pharmacology The Involvement of Post-Translational Modifications in Alzheimer's Disease
Current Alzheimer Research Peptide Sequence Prediction Supported by Correlation-Associated Networks in Human Cerebrospinal Fluid
Combinatorial Chemistry & High Throughput Screening Current Updates on the Regulation of Beta-Secretase Movement as a Potential Restorative Focus for Management of Alzheimer's Disease
Protein & Peptide Letters Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment
Current Drug Targets An Antioxidant Role by Minocycline Via Enhancing the Activation of LKB1/AMPK Signaling in the Process of Cerebral Ischemia Injury
Current Molecular Medicine Design of Some New Potent Beta-secretase Inhibitors Based on QSAR and Molecular Modeling Study on a Series of Hydroxyethylamine Derivatives
Letters in Drug Design & Discovery